| Name | RTC13 |
|---|---|
| Synonyms |
(5Z)-2-Amino-5-[[5-(2-nitrophenyl)-2-furanyl]methylene]-4(5H)-thiazolone
(Z)-2-amino-5-((5-(2-nitrophenyl)furan-2-yl)methylene)thiazol-4(5H)-one 4(5H)-Thiazolone, 2-amino-5-[[5-(2-nitrophenyl)-2-furanyl]methylene]-, (5Z)- |
| Description | RTC13 restores dystrophin expression and improves muscle function in the mdx mouse model for Duchenne muscular dystrophy (DMD)[1]. |
|---|---|
| Related Catalog | |
| In Vivo | Animal Model: Wild-type (C57BL/10) mice at 10 to 12 weeks of age[1]. Dosage: 10 (n = 5), 30 (n = 5), 60 (n = 5) or 300 mg/kg (n = 5). Administration: Intraperitoneal Administration. Result: No changes were observed in liver and kidney weights at the time of necropsies, and Hematoxylin and Eosin (H&E) staining revealed the absence of histopathological changes. |
| References |
| Molecular Formula | C14H9N3O4S |
|---|---|
| Molecular Weight | 315.30 |
| Exact Mass | 315.03100 |
| PSA | 139.71000 |
| LogP | 3.44290 |